Tuberculosis and Transplantation.
Mycobacterium tuberculosis is a major opportunistic pathogen in transplant recipients. Compared to that in the general population, the frequency of tuberculosis (TB) is 10 to 40 times higher in hematopoietic stem cell transplant (HSCT) recipients and 20 to 74 times higher in solid-organ transplant (SOT) recipients. Transplant recipients with TB are also more likely to develop disseminated disease, have longer time to definitive diagnosis, require more invasive diagnostic procedures, and experience greater anti-TB treatment-related toxicity than the general population. Specific risk factors for TB in SOT recipients include previous exposure to M. tuberculosis (positive tuberculin skin tests and/or residual TB lesions in pretransplant chest X ray) and the intensity of immunosuppression (use of antilymphocyte antibodies, type of basal immunosuppression, and intensification of immunosuppressive therapy for allograft rejection). Risk factors in HSCT recipients are allogeneic transplantation from an unrelated donor; chronic graft-versus-host disease treated with corticosteroids; unrelated or mismatched allograft; pretransplant conditioning using total body irradiation, busulfan, or cyclophosphamide; and type and stage of primary hematological disorder. Transplant recipients with evidence of prior exposure to M. tuberculosis should receive treatment appropriate for latent TB infection. Optimal management of active TB disease is particularly challenging due to significant drug interactions between the anti-TB agents and the immunosuppressive therapy. In this chapter, we address the epidemiology, clinical presentation, diagnostic considerations, and management strategies for TB in SOT and HSCT recipients.
University Hospital 12 de Octubre, Unit of Infectious Diseases, 28041 Madrid, Spain.
José M
JM
Aguado
University Hospital 12 de Octubre, Unit of Infectious Diseases, 28041 Madrid, Spain.
José Tiago
JT
Silva
University of Pittsburgh Medical Center, Infectious Diseases Section, Pittsburgh, PA 15213.
Palash
P
Samanta
University of Pittsburgh Medical Center, Infectious Diseases Section, Pittsburgh, PA 15213.|VA Pittsburgh Healthcare System and University of Pittsburgh, Pittsburgh, PA 15240.
Nina
N
Singh
D006801:Humans; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D012307:Risk Factors; D014180:Transplantation / Q000009:adverse effects / Q000706:statistics & numerical data*; D014376:Tuberculosis / Q000453:epidemiology* / Q000276:immunology